Characterization of KIFAP3, a Modifier of Survival in Sporadic ALS
KIFAP3(散发性 ALS 生存调节因子)的表征
基本信息
- 批准号:7889905
- 负责人:
- 金额:$ 35.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-15 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AllelesAmyotrophic Lateral SclerosisAutopsyAxonal TransportBindingCarrier ProteinsCellular StructuresComplexDevelopmentDiseaseEmbryoFDA approvedFamilial Amyotrophic Lateral SclerosisGene MutationGenesGeneticHomozygoteHumanKRP proteinKinesinLongevityMediatingMicrotubulesMotor NeuronsMusMutationNeurodegenerative DisordersPatientsPharmaceutical PreparationsPlayProteinsReportingRiluzoleRoleSOD1 geneSpinal CordTissuesTransgenic Organismsage relatedgenetic variantgenome wide association studymolecular pathologymouse modelmutantnovel strategiesprotein aggregatepublic health relevancesurvival motor neuron genetherapy developmenttreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Amyotrophic lateral sclerosis (ALS) is a uniformly lethal, age-dependent neurodegenerative disorder with a typical survival of 2-5 years. With the possible exception of reduced numbers of copies of the SMN gene, or the presence of the SOD1A4V gene mutation, genetic factors that influence survival in ALS have not been described. We recently reported that survival in sporadic ALS is enhanced by genetic variants that reduce expression of KIFAP3, a protein constituent of a kinesin II complex that mediates fast anterograde axonal transport. Homozygotes for the favorable allele have a survival advantage of 14.0 months, a substantial improvement (~42%) that surpasses the magnitude of benefit of the single drug (riluzole) that is FDA approved for ALS in ALS. A recent study documents that KIFAP3 binds misfolded SOD1G93A in ALS mice and is co-localized with the mutant SOD1 protein in aggregates both in the SOD1G93A mouse and in spinal cords of ALS patients bearing mutations in the SOD1 gene. These findings support the view that axonal transport proteins, and KIFAP3 in particular, are determinants of motor neuron viability. This proposal will investigate the mechanisms by which decreased expression of KIFAP3 increases survival in ALS. The Specific Aims of this proposal are to: (1) Analyze the interactions between KIFAP3, SOD1 and other cargoes in human sporadic ALS spinal cords. Hypothesis: Misfolded, wild-type SOD1 binds to KIFAP3 in sporadic ALS but not control spinal cords. (2) Determine the effect of reduced KIFAP3 expression on motor neuron viability and survival in transgenic SOD1G93A mice. Hypothesis: By analogy with survival in human ALS, motor neuron viability and survival in transgenic ALS mice will be enhanced by reduced expression of KIFAP3. (3) Analyze the interactions between KIFAP3, SOD1 and other cargoes in spinal cord from ALS and control mice with normal and reduced levels of KIFAP3. Hypothesis: Decreased expression of KIFAP3 will alter the types and quantities of cargoes transported by KIFAP3. (4) Determine the influence of altered expression levels of KIFAP3 on axonal transport rates in embryonic motor neurons from ALS and control mice. Hypothesis: Altered levels of KIFAP3 expression are not determinants of axonal transport rates. Our proposed studies will elucidate the mechanisms whereby KIFAP3 expression modulates survival in ALS. In the long term, understanding how KIFAP3 influences survival will facilitate the development of therapies to extend the lifespan of ALS patients.
PUBLIC HEALTH RELEVANCE: Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a uniformly lethal, age-dependent neurodegenerative disorder with a typical survival of 2 to 5 years. Through our efforts, we have identified a gene which can influence the survival advantage of sporadic ALS by 14.0 months, a substantial increment (42%) in this disease. The purpose of this proposal is to understand how this gene influences survival, which will aid in the development of treatment strategies to extend the lifespan of patients afflicted with ALS.
描述(由申请人提供):肌萎缩性侧索硬化症(ALS)是一种致命的、年龄依赖性的神经退行性疾病,典型生存期为2-5年。可能除了SMN基因拷贝数减少或SOD1A4V基因突变的存在外,影响ALS患者生存的遗传因素尚未被描述。我们最近报道,散发性ALS患者的生存率通过降低KIFAP3表达的遗传变异而提高,KIFAP3是一种介导快速顺行轴突运输的激酶II复合体的蛋白质成分。有利等位基因的纯合子具有14.0个月的生存优势,这是一个显著的改善(~42%),超过了FDA批准用于治疗ALS的单一药物(利鲁唑)的获益幅度。最近的一项研究表明,在ALS小鼠中,KIFAP3结合错误折叠的SOD1G93A,并与突变的SOD1蛋白共定位,聚集在SOD1G93A小鼠和SOD1基因突变的ALS患者脊髓中。这些发现支持轴突转运蛋白,特别是KIFAP3,是运动神经元活力的决定因素的观点。本研究将探讨KIFAP3表达降低提高ALS患者生存率的机制。本提案的具体目的是:(1)分析人类散发性ALS脊髓中KIFAP3、SOD1和其他基因的相互作用。假设:在散发性ALS中,错误折叠的野生型SOD1与KIFAP3结合,但不控制脊髓。(2)测定KIFAP3表达降低对转基因SOD1G93A小鼠运动神经元活力和存活的影响。假设:与人类ALS的存活类似,通过降低KIFAP3的表达,可以提高转基因ALS小鼠的运动神经元活力和存活。(3)分析ALS脊髓中KIFAP3、SOD1与其他物质的相互作用,并对照KIFAP3水平正常和降低的小鼠。假设:KIFAP3表达的降低会改变由KIFAP3运输的货物的种类和数量。(4)确定KIFAP3表达水平改变对ALS和对照小鼠胚胎运动神经元轴突转运率的影响。假设:KIFAP3表达水平的改变不是轴突运输速率的决定因素。我们提出的研究将阐明KIFAP3表达调节ALS生存的机制。从长远来看,了解KIFAP3如何影响生存将有助于开发延长ALS患者寿命的治疗方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOHN E LANDERS其他文献
JOHN E LANDERS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOHN E LANDERS', 18)}}的其他基金
Comprehensive Harmonization and Analysis of Case/Control Whole Genome Sequencing Data from the ALS/FTD Compute Project
来自 ALS/FTD 计算项目的病例/对照全基因组测序数据的全面协调和分析
- 批准号:
10592917 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Identification of genes causative for familial ALS gene using exome sequencing
使用外显子组测序鉴定导致家族性 ALS 基因的基因
- 批准号:
8628195 - 财政年份:2011
- 资助金额:
$ 35.96万 - 项目类别:
Identification of genes causative for familial ALS gene using exome sequencing
使用外显子组测序鉴定导致家族性 ALS 基因的基因
- 批准号:
8086646 - 财政年份:2011
- 资助金额:
$ 35.96万 - 项目类别:
Identification of genes causative for familial ALS gene using exome sequencing
使用外显子组测序鉴定导致家族性 ALS 基因的基因
- 批准号:
8433440 - 财政年份:2011
- 资助金额:
$ 35.96万 - 项目类别:
Identification and Characterization of ALS/FTD Associated Variants Using Whole Genome Sequencing
使用全基因组测序鉴定和表征 ALS/FTD 相关变异
- 批准号:
10216070 - 财政年份:2011
- 资助金额:
$ 35.96万 - 项目类别:
Identification of genes causative for familial ALS gene using exome sequencing
使用外显子组测序鉴定导致家族性 ALS 基因的基因
- 批准号:
8296297 - 财政年份:2011
- 资助金额:
$ 35.96万 - 项目类别:
Characterization of KIFAP3, a Modifier of Survival in Sporadic ALS
KIFAP3(散发性 ALS 生存调节因子)的表征
- 批准号:
8233455 - 财政年份:2010
- 资助金额:
$ 35.96万 - 项目类别:
Characterization of KIFAP3, a Modifier of Survival in Sporadic ALS
KIFAP3(散发性 ALS 生存调节因子)的表征
- 批准号:
8056035 - 财政年份:2010
- 资助金额:
$ 35.96万 - 项目类别:
Characterization of KIFAP3, a Modifier of Survival in Sporadic ALS
KIFAP3(散发性 ALS 生存调节因子)的表征
- 批准号:
8433438 - 财政年份:2010
- 资助金额:
$ 35.96万 - 项目类别:
Mannose-Binding Lectin Haplotypes and Infection Risk
甘露糖结合凝集素单倍型和感染风险
- 批准号:
6793437 - 财政年份:2004
- 资助金额:
$ 35.96万 - 项目类别:
相似海外基金
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
- 批准号:
MR/Y014901/1 - 财政年份:2024
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
Dysregulation of RNA processing as a driver of motor neuron dysfunction in Amyotrophic Lateral Sclerosis
RNA 加工失调是肌萎缩侧索硬化症运动神经元功能障碍的驱动因素
- 批准号:
MR/Y014286/1 - 财政年份:2024
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
Fasciculation IN Amyotrophic Lateral Sclerosis Using MUMRI (FINALSUM)
使用 MUMRI 治疗肌萎缩侧索硬化症的肌束颤动 (FINALSUM)
- 批准号:
MR/Y503502/1 - 财政年份:2024
- 资助金额:
$ 35.96万 - 项目类别:
Research Grant
I-Corps: Developing A Blood-Based Biomarker for the Detection and Monitoring of Amyotrophic Lateral Sclerosis
I-Corps:开发一种基于血液的生物标志物,用于检测和监测肌萎缩侧索硬化症
- 批准号:
2317745 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Standard Grant
Development of CM-CS1 CAR Treg to Treat Amyotrophic Lateral Sclerosis (ALS)
开发 CM-CS1 CAR Treg 治疗肌萎缩侧索硬化症 (ALS)
- 批准号:
10696512 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Targeted immunotherapy for amyotrophic lateral sclerosis and frontotemporal dementia
肌萎缩侧索硬化症和额颞叶痴呆的靶向免疫治疗
- 批准号:
10759808 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Metrics for Brain Controlled Communication: A comprehensive review of clinical outcome assessments for communication brain computer interfaces in amyotrophic lateral sclerosis
脑控制通信指标:肌萎缩侧索硬化症通信脑机接口临床结果评估的全面综述
- 批准号:
10848139 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Resolving the Role of Neuronal STING in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
解决神经元 STING 在肌萎缩侧索硬化症和额颞叶痴呆中的作用
- 批准号:
10606865 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
The Gut Microbiota as a Contributor to Sexual Dimorphism in Amyotrophic Lateral Sclerosis
肠道微生物群是肌萎缩侧索硬化症性别二态性的一个促成因素
- 批准号:
488892 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Operating Grants
The biochemical stratification of amyotrophic lateral sclerosis
肌萎缩侧索硬化症的生化分层
- 批准号:
MR/Y001095/1 - 财政年份:2023
- 资助金额:
$ 35.96万 - 项目类别:
Fellowship